Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Translate Bio's peak revenue was $7.8M in 2019. The peak quarterly revenue was $3.9M in 2019(q4).
Translate Bio's revenue increased from $1.4m in 2018 to $6.6M currently. That's a 361.95% change in annual revenue.
| Fiscal year / year | Translate Bio revenue |
|---|---|
| 2018 | $1.4M |
| 2019 | $7.8M |
| 2020 | $6.6M |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | $238,000 | $1.2M |
| 2019 | $1.5M | $1.2M | $1.3M | $3.9M |
| 2020 | $1.4M | $1.6M | $1.6M | $1.9M |
| 2021 | $2.3M | $2.8M | - | - |
Do you work at Translate Bio?
Did Translate Bio meet its revenue projections?
| CEO | Ronald C. Renaud Jr |
| Company Type | Public |
| Employees Number | 122 |
| Date Founded | 2011 |
| Headquarters | Lexington, Massachusetts |
| Revenue | $6.6M |
| Net Income | -$53,787,000 |
| Gross Proft | $3.6M (2020) |
| Tax Rate | -0.0% |
| Total Assets | $889,936,000 |
| Ticker | TBIO |
Translate Bio received early financing of $2.7M on 2011-11-30.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $2.7M | 11/2011 |
| Series A | $20.7M | 01/2012 |
| Series B | $63.8M | 07/2015 |
| Series C | $51M | 01/2017 |
| Series C | $42M | 12/2017 |
| Post Ipo Equity | $47.5M | 05/2019 |
| Investors | Security type |
|---|---|
| SR One | Series A |
| MERCK VENTURES BV | Series A |
| Partners Innovation Fund | Series A |
| Omega Funds | Series A |
| Atlas Venture | Series A |
| Monsanto Growth Ventures (MGV) | Series A |
| SR One | Series B |
| Partners Innovation Fund | Series B |
| Baupost Group | Series B |
| MRL Ventures Fund LLC | Series B |
| Pfizer Venture Investments | Series B |
| Omega Funds | Series B |
| Fidelity Management & Research Co LLC | Series B |
| Atlas Venture | Series B |
| Brookside Capital Inc | Series B |
| MERCK VENTURES BV | Series B |
| Leerink Partners LLC | Series B |
| Rock Springs Capital | Series B |
| Monsanto Growth Ventures (MGV) | Series B |
| SR One | Series C |
| Baupost Group | Series C |
| MRL Ventures Fund LLC | Series C |
| Omega Funds | Series C |
| Atlas Venture | Series C |
| Fidelity Management & Research Co LLC | Series C |
| Baupost Group | Series C |
| Omega Funds | Series C |
| Fidelity Management & Research Co LLC | Series C |
Zippia gives an in-depth look into the details of Translate Bio, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Translate Bio. The employee data is based on information from people who have self-reported their past or current employments at Translate Bio. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Translate Bio. The data presented on this page does not represent the view of Translate Bio and its employees or that of Zippia.
Translate Bio may also be known as or be related to TRANSLATE BIO, INC., Translate Bio and Translate Bio, Inc.,.